Thinking · Standards

BRSR, ESRS, GRI, ISSB: which standard asks whether care actually reached anyone?

Abhijith Magal · 16 September 2026 · 10 min read

This is a decision aid, not an explainer. The four regimes below are each defined elsewhere on this site, and each has its own page in the guide. This page compares them on one axis only: does the standard oblige a company to say anything about whether its health commitments reached people once climate disruption is counted?

The answer is no, for all four. That is not a complaint about the standards. They were each built to answer a different question, and they answer it. It is the finding this practice rests on, and it is worth setting out clause by clause, because a finding that rests on impressions is worth nothing to a reporting team.

Does any standard ask whether health commitments reached people during climate disruption?

No. Each regime asks about climate, and some ask about health or access, but none asks about the connection. The comparison below reads each standard's own disclosures, and the pattern is the same in all four: climate sits in one set of disclosures, people sit in another, and nothing requires a company to say what the first did to the second.

Which standard comes closest?

GRI, by a clear margin. GRI 102: Climate Change 2025, effective for reports and other materials published on or after 1 January 2027, adds a climate change adaptation plan disclosure, 102-2, and a just transition disclosure, 102-3, covering impacts on workers and communities. Those two open the door. An adaptation plan that covers a health programme could report whether the programme held through a climate event. Nothing in the standard requires it to.

The just transition disclosure is aimed at a different question: the social impact of the organisation's own move to a low-carbon economy on workers, Indigenous peoples and communities. It asks what the company's climate strategy does to people. It does not ask what the climate does to the people a company has committed to serve.

What about ISSB and SASB, which do mention access?

They hold both halves of the question in separate places. IFRS S2 asks about climate-related physical risk to the entity: storms, floods, drought and heatwaves, and how they could affect the company's prospects. SASB's Biotechnology & Pharmaceuticals Standard, which the ISSB took responsibility for in August 2022, carries an access to medicines topic. Metric HC-BP-240a.1 asks for a description of actions and initiatives to promote access to health care products for priority diseases and in priority countries, as the Access to Medicine Index defines them.

A pharmaceutical company applying both can describe its access programmes in one section and its flood exposure in another, fully compliant, without either section mentioning the other. That is the clearest single illustration of the gap on this page. The metric exists. The climate risk disclosure exists. The sentence connecting them does not.

The metric exists. The climate risk disclosure exists. The sentence connecting them does not.

Why do BRSR and ESRS miss it?

Structure. BRSR asks about employee and worker wellbeing under Principle 3 and about the environment under Principle 6, and the two principles never meet, which is set out in detail in BRSR Core and the health and climate disclosures most companies under-report. ESRS is more flexible. Its double materiality assessment could, in principle, find that climate disruption is a material impact on affected communities or on consumers and end-users. Whether it does depends on what the company knows about its own access data, which in most cases is nothing, because nobody has read that data against climate events. The CSRD after Omnibus I page covers what that means for a subsidiary.

What can a reporting team disclose voluntarily inside the existing structure?

One line per regime, in a disclosure that already exists. None of these invents a new indicator, and each can be defended as a reasonable reading of what the standard already allows.

• BRSRA voluntary line beside the Principle 3 wellbeing numbers: hours lost to heat or flood at the most exposed sites, measured the same way each year.
• ESRSTest climate disruption to programme reach explicitly in the double materiality assessment for affected communities and consumers, and record the result either way.
• GRIUnder the 102-2 adaptation plan, report whether the company's health programmes held through the year's main climate events, and which of the four climate-access conditions failed where they did not.
• ISSB with SASBIn the S2 physical risk narrative, name the access programmes reported under HC-BP-240a.1 that sit in the highest-rated hazard locations, and say what happened to them in the last hazard season.

Each line needs the same underlying record: programme activity laid against climate events, by week and location. Physical risk against access risk sets out the three steps that produce it from data a company already holds.

What happens to this gap next?

Toward convergence on climate, and silence on access. GRI and the IFRS Foundation have been aligning emissions disclosures, the revised ESRS were written with interoperability in mind, and BRSR is building its assessment glide path. None of that movement touches the question on this page. A company that answers it voluntarily, with a consistent measure and a clear coverage statement, will be ahead of every standard for as long as the standards stay silent. The four conditions are defined in what is climate-access, and the argument for why they matter is in climate change is a healthcare story.

Questions worth asking after this

Does any sustainability reporting standard require climate-health access disclosure?

No. BRSR, ESRS, GRI and the ISSB standards with SASB each address climate, and some address health or access, but none requires a company to disclose whether its health commitments reached people once climate disruption is counted.

Which reporting standard comes closest to covering climate and health access?

GRI 102: Climate Change 2025, effective for reports published from 1 January 2027, comes closest. Its adaptation plan disclosure, 102-2, and just transition disclosure, 102-3, create room to report on climate-disrupted access, though neither requires it.

Does SASB ask pharmaceutical companies about access to medicines?

Yes. The SASB Biotechnology and Pharmaceuticals Standard, now maintained by the ISSB, includes metric HC-BP-240a.1, a description of actions and initiatives to promote access to health care products for priority diseases and in priority countries. It does not ask how climate disruption affects that access.

Abhijith Magal

Founder, Syntropy Earth. Nine years across two global pharmaceutical multinationals in patient access and commercial roles, with health-equity work alongside the WHO-Foundation and UNICEF. He works on climate-access: where climate disruption breaks the link between patients and care. More about Abhijith →

This page compares published standards on a single question. It is not a complete description of any standard, and it is not reporting or assurance advice.

Last updated: 24 September 2026